Long-term comparative outcomes of rituximab and belimumab in lupus patients. (PubMed, Rheumatology (Oxford)) - Oct 15, 2026 - "In this observational cohort, belimumab was associated with similar rates of low disease activity as rituximab. Drug survival differed and warrants further study."
Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
David R W Jayne; Frances C Hall; Hugo Tordesillas; Iftach Sagy; Jane Hollis; Kevin W Loudon; Lisa Willcocks; Rachel B Jones; Rona M Smith
|